Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@article{Amin2010ResiliencyAV,
  title={Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.},
  author={Dhara N. Amin and Natalia V. Sergina and Deepika Ahuja and Martin McMahon and Jimmy A Blair and Donghui Wang and Byron Hann and Kevin Koch and Kevan M. Shokat and Mark M. Moasser},
  journal={Science translational medicine},
  year={2010},
  volume={2 16},
  pages={16ra7}
}
About 25% of breast cancers harbor the amplified oncogene human epidermal growth factor receptor 2 (HER2) and are dependent on HER2 kinase function, identifying HER2 as a vulnerable target for therapy. However, HER2-HER3 signaling is buffered so that it is protected against a nearly two-log inhibition of HER2 catalytic activity; this buffering is driven by the negative regulation of HER3 by Akt. We have now further characterized HER2-HER3 signaling activity and have shown that the compensatory… CONTINUE READING
73 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

A phase I/II study [abstract 1004

  • R. Swaby, K. Blackwell, +8 authors Neratinib in combination with trastuzumab for the treatment cancer
  • J. Clin. Oncol. 27, 15S
  • 2009
1 Excerpt

What have we learned so far? Target Oncol

  • E. de Azambuja, P. L. Bedard, T. Suter, M. Piccart-Gebhart, Cardiac toxicity with anti-HER-2 therapies
  • 4, 77–88
  • 2009

Similar Papers

Loading similar papers…